Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
4,646 total articles
Jorey Chernett, a 10% holder of Neuronetics, purchased 500,000 shares on March 27, 2026, paying between $1.28 and $1.41 per share for a total outlay of $675,000. The trade leaves Chernett with 9,393,276 shares. The transaction comes alongside Neuronetics' fourth-quarter 2025 results, which showed revenue above forecasts but an EPS shortfall, and a …
Horace Mann Educators Corp Chief Marketing Officer Steven R. Chauby bought 180 shares on March 26, 2026, spending $7,632 at $42.40 per share. The purchase leaves Chauby with 4,643.023 shares directly and 500 shares indirectly through a domestic partner. The $1.7 billion insurance company reported Q4 2025 results that exceeded analysts' expectations…
IperionX Ltd (NASDAQ: IPX) President Toby Edgcumbe Symonds purchased 11,000 American Depository Shares on March 27, 2026, for $23.8684 apiece, totaling $262,552. The trade comes while the stock trades near $23.15 and has fallen 53% over six months. Recent analyst initiations from BTIG and William Blair accompany the transaction as IperionX starts c…
Rubin Shmuel, President and CEO of LightPath Technologies INC (NASDAQ: LPTH), purchased 180 shares of Class A common stock on March 27, 2026, spending roughly $1,745. The transaction comes amid a quarter that produced a revenue beat driven by defense and security demand, even as reported EPS fell short of forecasts and one analyst raised their pric…
Director Tripeny R Tony acquired 4,187 American Depositary Shares of IPERIONX Ltd on March 27, 2026, for $23.7554 per share, a transaction valued at $99,463. The purchase leaves the director with direct holdings across ADS, ordinary shares, and RSUs while the company moves into commercial production and receives new analyst coverage.
IperionX Ltd director Todd Hannigan acquired 225,225 ordinary shares on March 27, 2026, paying $3.20 per share for a total outlay of approximately $721,000. The purchase comes while the stock has fallen sharply over recent months even as the company begins commercial production at its Virginia facility and attracts positive analyst initiation.
Director George Jeffrey P. bought 5,592 shares of LENZ Therapeutics on March 27, 2026, paying a weighted average of $8.92 per share for a total of $49,890. The trade followed a 24% one-week decline that left the stock trading near a 52-week low. LENZ recently reported Q4 2025 results that included a solid cash position and early revenue from its pr…
Lenz Therapeutics CEO Evert B. Schimmelpennink bought 28,089 shares on March 27, 2026, spending about $251,410. The insider purchase comes while the stock trades near a 52-week low and after the company reported initial revenue from its presbyopia treatment VIZZ alongside a quarter marked by elevated operating costs and a net loss.
Daniel R. Chevallard, chief financial officer of LENZ Therapeutics, acquired 7,500 shares on March 27, 2026, for $8.57 per share, a transaction valued at $64,275. The purchase, disclosed on a Form 4 filing with the SEC, brings his direct ownership to 12,886 shares. The insider buy occurs as LENZ shares trade close to a 52-week low and after the com…
IperionX Ltd Chief Executive Anastasios Arima disclosed purchases on March 27, 2026 totaling $1.79 million. The transactions, reported on an SEC Form 4, included 467,000 Ordinary Shares and 12,800 American Depository Shares. The company recently began commercial production at its Virginia facility and is the subject of fresh analyst coverage and pr…
Nicholas D. Varischetti, a director of Farmers National Banc Corp (FMNB), purchased 2,000 shares on March 26, 2026, for $12.90 a share, a transaction valued at $25,800. The purchase price was near the prevailing market price of $12.88. InvestingPro data cited alongside the transaction shows the stock trading at a P/E ratio of 8.9 and yielding 5.28%…
Eric P. Lefkofsky, CEO and Chairman of Tempus AI, sold 151,520 shares of Class A common stock on March 26, 2026, in transactions conducted through entities he manages. The sales totaled $7,711,150 and were carried out at prices between $45.78 and $47.42. Despite the disposals, Lefkofsky still holds substantial positions across multiple entities and…
Gen IV Investment Opportunities and related entities sold 2,369,769 shares of Battalion Oil Corp (NASDAQ: BATL) on March 25, 2026, for $5.8206 per share, generating proceeds of $13,793,477. The filing shows the reporting owners no longer hold any Battalion shares. The transaction comes as the stock has exhibited extreme short-term swings and the co…
Glaukos NASDAQ:GKOS Senior Vice President and Chief Financial Officer Alex R. Thurman sold 2,511 shares on March 25, 2026, for $106.46 per share, totaling $267,321, under a Rule 10b5-1 trading plan. The transaction left Thurman with 41,967 shares held directly, including 5,230 unvested restricted stock units. On the same date he recorded acquisitio…
Dave & Buster's Entertainment Inc CEO Tarun Lal executed two purchases totaling $69,690 for the company’s common stock in September and October 2025. The transactions — 2,500 shares at $20.52 on September 18 and 1,000 shares at $18.39 on October 21 — leave Lal with 11,560 shares directly held. The stock has since fallen to $9.81, close to its 52-we…
Anaptysbio President and CEO Daniel Faga sold 16,571 shares on March 27, 2026, to meet tax withholding obligations tied to recently vested performance-based restricted stock units. The company is moving ahead with a planned April 20, 2026 spinoff of First Tracks Biotherapeutics, which raised $80 million in a private placement, and its board has app…
Director Juan Jose Chacon Quiros sold 3,575 shares of Establishment Labs Holdings Inc. (NASDAQ: ESTA) on March 25, 2026, in a transaction totaling approximately $214,768. The sale was executed under a pre-arranged Rule 10b5-1 trading plan. Separately, Establishment Labs reported fourth-quarter 2025 results that exceeded expectations, with an EPS of…
Adam Crystal, President of R&D at Tango Therapeutics (TNGX), sold 12,000 shares on March 25, 2026, realizing roughly $241,320, and simultaneously exercised options to acquire 12,000 shares at a $5.20 strike. The transactions were carried out under a Rule 10b5-1 plan adopted on October 27, 2025. Tango reported a net loss of $38.7 million in Q4 2025 …
Apogee Therapeutics CFO Jane Henderson sold 2,000 shares of the company’s common stock on March 25, 2026, for $85.00 per share, netting $170,000. The transaction was executed under a Rule 10b5-1 trading plan adopted on September 2, 2025. The move comes amid a flurry of capital-raising activity by the company and after an analyst raised its price ta…
CoreWeave CEO and President Michael N. Intrator sold 42,693 shares of Class A stock on March 25, 2026, collecting $7,202,031 in proceeds. The trades, executed under a Rule 10b5-1 plan adopted May 23, 2025, occurred at prices between $85.5971 and $88.2534. Intrator still holds 5,666,501 shares directly following the transactions. On the same day he …
Inspired Entertainment Director Michael R. Chambrello bought $69,240 worth of common stock on March 26, 2026, bringing his direct holdings to 64,568 shares. The purchases occurred while the stock traded below InvestingPro's fair value estimate; the company reported fourth-quarter 2025 results that beat revenue expectations but missed on EPS, and pr…
James H. Dahl, listed as a 10% owner of AMREP CORP (NASDAQ: AXR), bought 4,000 shares on March 26, 2026, spending $105,210 across multiple trades executed between $25.4356 and $27.164 per share. The purchases raise his direct stake to 474,398 shares while he also holds additional shares indirectly through IRAs and a trust. The stock has returned 38…
Sandeep Bharathi, president of Marvell Technology's Data Center Group, sold 44,414 shares on March 26, 2026, for about $4.42 million under a 10b5-1 plan. The transaction came as Marvell introduced the Structera S 60260 PCIe 6.0 switch, declared a quarterly dividend, and retained Buy ratings from Stifel and UBS amid its partnerships and revenue targ…
Inspired Entertainment President and CEO Pierce Brooks H. completed a series of open-market purchases March 25-27, 2026, totaling $136,633. The trades increased his direct and indirect holdings in the company amid mixed fourth-quarter results and a continued analyst Market Outperform rating with an $11.00 price target.
Protagonist Therapeutics' Chief Financial Officer, Ali Asif, sold 24,765 shares of the company's common stock on March 26, 2026, for roughly $2.58 million at $104.24 per share. On the same day he exercised options to acquire an identical number of shares across two grants. The company recently received FDA approval for its psoriasis treatment Icoty…
